Literature DB >> 11474012

Molecular cloning and sequencing of the circumsporozoite protein gene from Plasmodium falciparum strain FCC-1/HN and expression of the gene in Mycobacteria.

C Zheng1, P Xie, Y Chen.   

Abstract

Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used as a live bacterial vaccine to immunize more than 2 billion people against tuberculosis. In an attempt to use this vaccine strain as a vehicle for protective antigens, the Plasmodium falciparum gene from strain FCC-1/HN encoding circumsporozoite protein (CSP) was amplified from the P. falciparum genome, sequenced, and expressed in M. bovis BCG under the control of an expression cassette carrying the promoter of heat shock protein 70 (HSP70) from Mycobacterium tuberculosis. The recombinant shuttle plasmid pBCG/CSP was introduced into mycobacteria by electroporation, and the recombinant mycobacteria harboring pBCG/CSP could be induced by heating to express CSP; the molecular mass of recombinant CSP was about 42 kDa. This report of expression of the almost-full-length P. falciparum CSP gene in BCG provides scientific evidence for the application of the HSP70 promoter in expressing a foreign gene in BCG and in development of BCG as a multivalent vectoral vaccine for malaria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474012      PMCID: PMC88259          DOI: 10.1128/JCM.39.8.2911-2915.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

Review 1.  Rationale for the development of an engineered sporozoite malaria vaccine.

Authors:  V Nussenzweig; R S Nussenzweig
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Development of a sporozoite malaria vaccine.

Authors:  V Nussenzweig; R S Nussenzweig
Journal:  Am J Trop Med Hyg       Date:  1986-07       Impact factor: 2.345

Review 3.  The genetic reconstruction of BCG as a new immunotherapeutic tool.

Authors:  M A O'Donnell
Journal:  Trends Biotechnol       Date:  1997-12       Impact factor: 19.536

4.  Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum.

Authors:  S Kumar; L H Miller; I A Quakyi; D B Keister; R A Houghten; W L Maloy; B Moss; J A Berzofsky; M F Good
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

5.  Sequence variation in putative functional domains of the circumsporozoite protein of Plasmodium falciparum. Implications for vaccine development.

Authors:  V F de la Cruz; A A Lal; T F McCutchan
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

6.  Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.

Authors:  W R Ballou; S L Hoffman; J A Sherwood; M R Hollingdale; F A Neva; W T Hockmeyer; D M Gordon; I Schneider; R A Wirtz; J F Young
Journal:  Lancet       Date:  1987-06-06       Impact factor: 79.321

7.  Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria.

Authors:  P Romero; J L Maryanski; G Corradin; R S Nussenzweig; V Nussenzweig; F Zavala
Journal:  Nature       Date:  1989-09-28       Impact factor: 49.962

Review 8.  Antisporozoite vaccine for malaria: experimental basis and current status.

Authors:  R S Nussenzweig; V Nussenzweig
Journal:  Rev Infect Dis       Date:  1989 May-Jun

9.  Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites.

Authors:  D F Clyde
Journal:  Am J Trop Med Hyg       Date:  1975-05       Impact factor: 2.345

10.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.

Authors:  D A Herrington; D F Clyde; G Losonsky; M Cortesia; J R Murphy; J Davis; S Baqar; A M Felix; E P Heimer; D Gillessen
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.